Clinical Trials

466 enrolled

Ovarian Neoplasms

NCT06915025 2026-04-13

OVATION-3

500 enrolled

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04498117 2026-04-01

FLORA-5

615 enrolled

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT04095364 2026-03-24

Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

450 enrolled

Phase 3 Not yet recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07286266 2026-03-19

A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)

450 enrolled

Ovarian Neoplasms

NCT05281471 2026-03-18

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

186 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms, Vaccinia

NCT04729387 2026-03-13

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

358 enrolled

Ovarian Neoplasms

NCT05116189 2026-03-09

KEYNOTE-B96

643 enrolled 17 charts 3 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02446600 2026-03-05

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

579 enrolled 17 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06619236 2026-03-03

RAINFOL-02

530 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00565851 2025-12-30

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

1,052 enrolled 27 charts

Brenner Tumor, Carcinoma, Adenocarcinoma, Mucinous, Fallopian Tube Neoplasms, Ovarian Neoplasms, Adenocarcinoma, Clear Cell

NCT06855069 2025-12-17

HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

468 enrolled

Ovarian Neoplasms

NCT06476184 2025-12-05

SALVOVAR

250 enrolled

Ovarian Neoplasms

NCT01081262 2025-11-25

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer

50 enrolled 13 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03740165 2025-10-22

KEYLYNK-001

1,367 enrolled 29 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT04908787 2025-09-11

A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer

421 enrolled

Ovarian Neoplasms

NCT05009082 2025-09-10

Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer

970 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05092360 2025-08-28

ARTISTRY-7

456 enrolled 19 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06828354 2025-03-24

A Study of SHR-A1811 in Subjects With Ovarian Cancer

300 enrolled

Phase 3 Not yet recruiting

Ovarian Neoplasms

NCT06751485 2024-12-31

JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer

430 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02470585 2024-10-26

VELIA

1,140 enrolled 29 charts

Ovarian Neoplasms

NCT04921527 2024-10-18

CHIPRO

454 enrolled

Ovarian Neoplasms, Recurrence

NCT03635489 2024-10-03

A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

100 enrolled 22 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03598270 2024-08-30

ANITA

417 enrolled

Ovarian Neoplasms

NCT06394492 2024-08-09

SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

440 enrolled

Ovarian Neoplasms

NCT03940196 2024-03-29

Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3)

540 enrolled

Ovarian Neoplasms

NCT00657878 2023-11-13

MITO-8

215 enrolled

Ovarian Neoplasms

NCT02584478 2023-11-08

AL3818

294 enrolled

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT04729608 2023-10-30

AXLerate-OC

366 enrolled

Ovarian Neoplasms

NCT04201561 2023-06-26

SELENIUM

68 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peripheral Nervous System Diseases

NCT02855944 2023-06-09

ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients

349 enrolled 29 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence

NCT02429687 2023-04-25

MOGCT-01

129 enrolled

Ovarian Germ Cell Cancer, Ovarian Neoplasms

NCT02429700 2023-04-25

SCST-01

132 enrolled

Ovarian Neoplasms

NCT00326456 2023-03-27

MITO-2: A Study Comparing 2 Chemotherapy Regimens (Carboplatin/Liposomal Doxorubicin vs Carboplatin/Paclitaxel) in Patients With Ovarian Cancer

820 enrolled

Ovarian Neoplasms

NCT00660842 2023-03-24

MITO-7

800 enrolled

Ovarian Neoplasms, Neurotoxicity Syndromes

NCT01802749 2023-03-24

MITO16MANGO2b

406 enrolled

Ovarian Neoplasms

NCT03038100 2023-02-17

IMagyn050

1,301 enrolled 22 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT03398655 2023-01-10

OVAL

408 enrolled

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT01462890 2022-07-20

BOOST

927 enrolled

Fallopian Tube Neoplasms, Genital Diseases, Female, Ovarian Diseases, Ovarian Neoplasms, Peritoneal Neoplasms

NCT00976911 2022-06-21

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

361 enrolled 15 charts

Ovarian Neoplasms

NCT03690739 2022-02-24

Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer

9 enrolled

Ovarian Neoplasms

NCT00954174 2021-09-30

Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer

637 enrolled 18 charts

GynecologicSarcoma

Carcinosarcoma, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04679064 2021-08-27

NItCHE-MITO33

427 enrolled

Ovarian Neoplasms

NCT03806049 2021-07-15

Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer

Phase 3 Withdrawn

Ovarian Neoplasms

NCT02631876 2020-10-14

FORWARD I

366 enrolled 20 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02718417 2020-07-14

JAVELIN OVARIAN 100

998 enrolled 39 charts

Ovarian Neoplasms

NCT00028743 2020-04-02

Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

819 enrolled

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03693248 2019-12-10

ROCOCO

298 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04000295 2019-10-08

Apatinib and Etoposide Capsule Versus Weekly Paclitaxel in Patients With Platinum Resistant Ovarian Cancer

280 enrolled